Skip to content
Search

Latest Stories

Pooja Hegde to star opposite Vijay in Nelson Dilipkumar’s next

Pooja Hegde to star opposite Vijay in Nelson Dilipkumar’s next

By Murtuza Iqbal

Vijay was last seen on the big screen in this year’s release Master which was a blockbuster at the box office. The actor will next be seen in Nelson Dilipkumar’s next which is tentatively titled Thalapathy 65.


While we knew that Vijay will be seen as the male lead in the film, the makers have now announced that Pooja Hegde will be playing the female lead in the movie.

Pooja took to Twitter to inform everyone about it. She tweeted, “SUPER DUPER EXCITED to be onboard this grand film with the fantastic @actorvijay Can’t wait to start shooting @Nelsondilpkumar @sunpictures @anirudhofficial Tamil cinema....here I come.... #Thalapathy65 #PoojaHegdeInThalapathy65.”

Pooja is a big star in the Telugu film industry and she is also trying to make a mark in Bollywood. However, the actress’ first film was a Tamil film titled Mugamoodi. So, Thalapathy 65 will mark her comeback in Tamil films, and it will be for the first time when we will get to see Pooja and Vijay on the big screen together.

Talking about other films of Pooja, the actress has her kitty full with movies like Most Eligible Bachelor (Telugu), Radhe Shyam (Telugu/Hindi), Cirkus (Hindi), and Acharya (Telugu).

Acharya will hit the silver screens on 13th May 2021, Most Eligible Bachelor is slated to release on 12th June 2021, and Radhe Shyam will hit the big screens on 30th July 2021. The release date of Cirkus is yet to be announced, but there are reports that the movie will release in December this year.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less